Your browser doesn't support javascript.
loading
Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAFV600E glioblastoma results in sustained response: A case report.
Wagle, Naveed; Sharma, Akanksha; Nguyen, Minhdan; Truong, Judy; Juarez, Tiffany M; Kesari, Santosh.
Afiliación
  • Wagle N; Pacific Neuroscience Institute, Saint John's Cancer Institute, Providence Saint John's Health Center, Saint Monica, California, USA.
  • Sharma A; Pacific Neuroscience Institute, Saint John's Cancer Institute, Providence Saint John's Health Center, Saint Monica, California, USA.
  • Truong J; Pacific Neuroscience Institute, Saint John's Cancer Institute, Providence Saint John's Health Center, Saint Monica, California, USA.
  • Juarez TM; Pacific Neuroscience Institute, Saint John's Cancer Institute, Providence Saint John's Health Center, Saint Monica, California, USA.
  • Kesari S; CureScience Institute, San Diego, California, USA.
Neurooncol Adv ; 6(1): vdae110, 2024.
Article en En | MEDLINE | ID: mdl-39036436
ABSTRACT
Radiation's confounding and adverse effects on tumor microenvironment and normal brain could potentially be delayed by upfront combination treatment. We present a patient with newly diagnosed BRAF V600E-mutant, PD-L1-positive glioblastoma treated with off-label RAF/MEK inhibitors encorafenib/binimetinib after progressing on postoperative immune checkpoint blockade and temozolomide (no radiation administered NCT03425292). Complete response occurred 6 months after adding encorafenib/binimetinib, and clinical benefit was sustained for over 20 months. Treatment was well tolerated with manageable toxicities, with quality of life and cognitive function maintained throughout treatment. Adding encorafenib/binimetinib to immunotherapy and temozolomide conferred favorable and lasting efficacy for our BRAF V600E -mutant glioblastoma patient, justifying future studies.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Neurooncol Adv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Neurooncol Adv Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido